Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cortoss to target vertebral compression fractures:

This article was originally published in Clinica

Executive Summary

Orthovita says that it plans to submit to European regulatory authorities by the end of 2002 data from a study that is assessing its Cortoss biomaterial as a means of repairing vertebral compression fractures. Cortoss, a synthetic cortical bone void filler, has been on sale in Europe since January 2002 for the fixation of bone screws used in patients with weak bone caused by osteoporosis. The new study is evaluating the ability of the product to provide pain relief by providing new stability to the fractured vertebra, says the Malvern, Pennsylvania firm.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT067435

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel